Published on in Vol 5 , No 3 (2016) :Jul-Sept

EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia

EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia

EXpanding Treatment for Existing Neurological Disease (EXTEND): An Open-Label Phase II Clinical Trial of Hydroxyurea Treatment in Sickle Cell Anemia

Angela E Rankine-Mullings 1 , MBBS, MRCPCH ;   Courtney R Little 2 , RN, BSN ;   Marvin E Reid 3 , MBBS, PhD ;   Deanne P Soares 3 , MBBS, DM ;   Carolyn Taylor-Bryan 3 , MBBS, DM ;   Jennifer M Knight-Madden 1 , MBBS, PhD ;   Susan E Stuber 2 , MA ;   Asha V Badaloo 3 , PhD ;   Karen Aldred 1 , MSc ;   Margaret E Wisdom-Phipps 1 , RN, RM ;   Teresa Latham 2 , MA ;   Russell E Ware 2 , MD, PhD

1 Sickle Cell Unit , Tropical Medicine Research Institute , University of the West Indies , Kingston , JM

2 Division of Hematology , Cincinnati Children’s Hospital Medical Center , Cincinnati , OH , US

3 Tropical Metabolism Research Unit , Tropical Medicine Research Institute , University of the West Indies , Kingston , JM

Corresponding Author: